PSH0 Stock Chart & Stats
€0.07
>-€0.01(-2.56%)
At close: 4:00 PM EDT
€0.07
>-€0.01(-2.56%)
Day’s Range― - ―
52-Week Range€0.05 - €0.20
Previous CloseN/A
Volume4.29K
Average Volume (3M)36.03K
Market Cap
€25.89M
Enterprise Value€56.09
Total Cash (Recent Filing)€63.33K
Total Debt (Recent Filing)€2.58M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Mar 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding377,642,520
10 Day Avg. Volume27,188
30 Day Avg. Volume36,034
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.62Price Target Upside785.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reusable Cell-Therapy PlatformThe Cell Pouch System offers a potentially reusable implant platform across chronic-disease applications, including insulin-dependent diabetes. If clinical development succeeds, a scalable platform could support multiple programs and create durable strategic value beyond a single therapy.
Improving Loss TrendThe substantial reduction in net losses indicates a lower spending profile or meaningful cost control relative to prior periods. Although profitability remains distant, continued improvement could extend development runway and reduce the pace at which external capital is required.
Lower Cash-Burn Run RateOperating cash outflows have declined materially from 2023 and 2024 levels, suggesting improved spending discipline or a narrower development footprint. A lower burn rate can preserve resources for priority clinical work and make future financing needs more manageable.
Bears Say
No Commercial RevenueWith no reported revenue base, Sernova has not yet demonstrated commercial traction or internally funded operations. Its financial outlook remains dependent on clinical progress, regulatory approval, and eventual commercialization of its therapies or platform.
Negative Shareholders’ EquityNegative shareholders’ equity signals accumulated financial pressure and leaves the company with limited balance-sheet resilience. This weak capital position can constrain strategic flexibility and increase dependence on future financing or other forms of external support.
Persistent External-Funding DependencePersistently negative operating and free cash flow show that development activities are not funded by operations. Sernova therefore remains reliant on equity financing, grants, or strategic arrangements, creating ongoing funding execution and potential dilution pressure.
Sernova News
PSH0 FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was €0.05 and its highest was €0.20 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is €25.89M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Mar 12, 2027 which is in 159 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Sep 10, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of -€0.004 by -€0.002.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Undervalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sernova have?
Sernova has 377,642,520 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -€0.006 in its last earnings report, missing expectations of -€0.004. Following the earnings report the stock price went down -30.526%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in DE:PSH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
PSH0 Stock 12 Month Forecast
Average Price Target
€0.62
▲(785.52% Upside)
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―